Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of PEP-Therapy.

    Client Virtual Booth

    PEP-THERAPY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    PEP-Therapy
    France Flag
    Country
    Country
    France
    Address
    Address
    Pépinière Paris Santé Cochin 29 rue du Faubourg Saint Jacques 75014 Paris
    Telephone
    Telephone
    +33 1 81 70 76 82
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pep-therapy.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers

    Details:

    PEP-Therapy's primary candidate, PEP-010, is currently undergoing early-stage clinical trials in combination with Paclitaxel/Gemcitabine for treating advanced or metastatic ovarian cancer and metastatic pancreatic ductal adenocarcinoma.


    Lead Product(s): PEP-010,Paclitaxel,Gemcitabine

    Therapeutic Area: Oncology Product Name: PEP-010

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 25, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase I Clinical Trial of PEP-010 for The Treatment of Advanced Solid Tumors

    Details:

    PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology for the treatment of advanced solid tumors.


    Lead Product(s): PEP-010

    Therapeutic Area: Oncology Product Name: PEP-010

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 05, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PEP-Therapy Extends Series-A Financing, Raising a Total of €5.4 Million

    Details:

    PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy's innovative Cell Penetrating & Interfering Peptide (CP&IP) technology.


    Lead Product(s): PEP-010

    Therapeutic Area: Oncology Product Name: PEP-010

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Anaxago

    Deal Size: $6.4 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing July 19, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PEP-Therapy Raises €2.75 Million in Series A Financing to Advance Its Lead Candidate, PEP-010, Into the Clinic

    Details:

    PEP-Therapy will use the funds to progress the clinical development of PEP-010, PEP-Therapy's lead Cell Penetrating & Interfering Peptide (CP&IP), for the treatment of advanced solid tumors.


    Lead Product(s): PEP-010

    Therapeutic Area: Oncology Product Name: PEP-010

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Italian Angels for Growth

    Deal Size: $3.5 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing April 22, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Pep-Therapy and Institut Curie Granted Approval from Ansm to Start First-in-Human Clinical Trial of Pep-010 for Advanced Solid Tumors

    Details:

    PEP-010 is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.


    Lead Product(s): PEP-010

    Therapeutic Area: Oncology Product Name: PEP-010

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 16, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search